Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
04/2003
04/02/2003CN1407993A Gene recombinant antibody and its fragment
04/02/2003CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor
04/02/2003CN1407984A 1,8-naphthyridin-2 (1H)-one derivatives
04/02/2003CN1407973A Butyne diol derivatives
04/02/2003CN1407972A 4-pyrimidine-N-acyl-L-phenylalanines
04/02/2003CN1407971A Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
04/02/2003CN1407970A Urea compounds having muscarinic receptor antagonist activity
04/02/2003CN1407968A Adamantane derivatives
04/02/2003CN1406618A Chinese herbal medicine preparation for treating bronchitis and laryngopharyngitis
04/02/2003CN1406613A Erbining capsules for rhinopathy
04/02/2003CN1406611A Medicine for cough and preparation thereof
04/02/2003CN1406523A Oral liquid production
04/02/2003CN1104422C Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
04/02/2003CN1104412C Benzamidine derivatives and use thereof as medicaments with LTB4-antagonistic effect
04/01/2003US6541670 Antiinflammatory agents
04/01/2003US6541669 Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis
04/01/2003US6541638 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction
04/01/2003US6541623 Sepsis shock therapy; rheumatic diseases; antiinflammatory agents; nucleotide sequence detector
04/01/2003US6541616 Exterior membrane; nucleotide sequence; induction immunology response
04/01/2003US6541605 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
04/01/2003US6541490 Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt
04/01/2003US6541485 Urea substituted imidazoquinolines
04/01/2003US6541482 Autoimmune disease
04/01/2003US6541474 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia
04/01/2003US6541471 Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist
03/2003
03/28/2003CA2404045A1 Use of coagulation factor vii-activating protease for the prophylaxis and therapy of vasoproliferative disorders
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025155A1 Fermentation product of cyptoporus volvatus and its preparation method and use
03/27/2003WO2003025121A2 Igf-binding protein-derived peptide or small molecule
03/27/2003WO2003025015A2 A soluble toll-like receptor
03/27/2003WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024962A1 Piperidine derivatives and their use as modulators of chemokine (especially ccr3) activity
03/27/2003WO2003024953A1 Propanolamine derivative having 1,4-benzodioxane ring
03/27/2003WO2003024929A1 Substituted piperidines with selective binding to histamine h3-receptor
03/27/2003WO2003024928A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
03/27/2003WO2003024922A1 Hydroxyfattysulfonic acid analogs
03/27/2003WO2003024921A1 Alkyl urea retinoid agonists i
03/27/2003WO2003024920A1 Substituted urea retinoid agonists ii
03/27/2003WO2003024488A2 Combination of a pde inhibitor and a leukotriene receptor antagonist
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024474A2 Anti-inflammatory agent
03/27/2003WO2003024464A1 Pharmaceutical composition containing valerina officinalis extract
03/27/2003WO2003024452A1 Novel medicaments for inhalation
03/27/2003WO2003024440A1 Salicylic acid salts, methods for the production and use thereof as medicaments
03/27/2003WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases
03/27/2003WO2003024433A2 Compositions for treatment of common cold, comprising ipratropium and xylometazoline
03/27/2003WO2003024396A2 Dry powder medicament formulations
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094019A9 Highly purified antiendotoxin compound
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002048358A3 Regulation of human chemokine-like receptor
03/27/2003WO2002040506A3 Modified clostridial neurotoxins with altered biological persistence
03/27/2003WO2002028844A1 Thiazole or oxazole derivatives
03/27/2003WO2002026774A3 Melanocortin receptor ligands
03/27/2003WO2002026229A1 Airway mucus secretion inhibitors
03/27/2003WO2002017880A3 Nitric oxide-producing hydrogel materials
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2002000692A3 Pd-l2 molecules: pd-1 ligands and uses therefor
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060627 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060461 Cyclic diamine compound with condensed-ring groups
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060455 Treating lung damage from smoke, endometriosis, Behcet's disease, ankylosing spondylitis, cancer, Lyme disease, and/or restenosis following agioplasty with 1-(4-t-butyl-phenyl)-3-(4-(6-morpholin-4-ylmethyl-peperidin-yl)naphthalen-1 -yl)-urea
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060399 A heat shock protein 20 (HSP20)-derived polypeptides for treating or inhibiting smooth muscle vasospasm, smooth muscle cell proliferation, migration, and vasoconstriction
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059874 Polypeptide for use in the treatment of autoimmune, inflammatatory, arthritic, atherosclerotic, allergenic, dermatitis, urticaria, adult respiratory distress syndrome, asthma, rhinitis, eczema and infections
03/27/2003US20030059869 Novel G protein-coupled receptor, GAVE3
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059856 Detection of modulator of receptor binding activity; obtain sample containing receptor, incubate with test agent and ligand, monitor binding activity of ligand, adjusment in binding activity indicates modulator
03/27/2003US20030059773 Immunomodulatory formulations and methods for use thereof
03/27/2003US20030059767 Zinc finger protein derivatives and methods therefor
03/27/2003US20030059430 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor
03/27/2003US20030059375 Method for treating lung cancers
03/27/2003US20030056788 Partial liquid breathing of fluorocarbons
03/27/2003CA2461073A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003CA2461072A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003CA2461071A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460719A1 Igf-binding protein-derived peptide or small molecule
03/27/2003CA2460578A1 Propanolamine derivative having 1,4-benzodioxane ring
03/27/2003CA2460544A1 Anti-inflammatory agent
03/27/2003CA2460460A1 Fermentation product of cryptoporus volvatus and its preparation method and use
03/27/2003CA2460442A1 Combination of a pde inhibitor and a leukotriene receptor antagonist
03/27/2003CA2460440A1 Salicylic acid salts, processes for preparing them and their use as pharmaceutical compositions
03/27/2003CA2460358A1 Hydroxyfattysulfonic acid analogs
03/27/2003CA2460263A1 Hydroxyeicosenoic acid analogs
03/27/2003CA2459773A1 Enamel matrix protein compositions for modulating immune response
1 ... 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 ... 878